- Development of Richter's transformation in a patient with refractory chronic lymphocytic leukaemia on ibrutinib therapy2020 | Faculty of Medicine in Hradec Králové
- Ibrutinib jako přemostění k alogenní transplantaci kostní dřeně2017 | Publication without faculty affiliation
- Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma2019 | First Faculty of Medicine
- Efekt léčby ibrutinibem u relapsu CLL po alogenní transplantaci krvetvorných buněk2017 | First Faculty of Medicine
- Synthesis of [13C6]-ibrutinib2021 | Faculty of Medicine in Hradec Králové
- New drugs in the treatment of B-lymphoproliferative disorders - highlights from ICML congress in Lugano, June 20132013 | Faculty of Medicine in Hradec Králové
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities2022 | Publication without faculty affiliation
- Ibrutinib v léčbě refrakterního lymfomu z plášťových buněk2019 | Third Faculty of Medicine
- Ibrutinib v léčbě pacientů s chemorefrakterním lymfomem z plášťových buněk2019 | Publication without faculty affiliation
- Treatment of relapsed chronic lymphocytic leukemia2019 | First Faculty of Medicine
- Research Report University Hospital for clinical evaluation of PCI-32765MCL3002Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CAPublication without faculty affiliation
- Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future2015 | First Faculty of Medicine
- Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy2020 | Second Faculty of Medicine
- Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse2022 | First Faculty of Medicine, Third Faculty of Medicine
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study2023 | Publication without faculty affiliation
- Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial2023 | Second Faculty of Medicine
- Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia2023 | First Faculty of Medicine
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové
- A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma2020 | First Faculty of Medicine
- Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab2023 | Third Faculty of Medicine
- Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia2022 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum2022 | Faculty of Medicine in Hradec Králové
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial2022 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study2020 | First Faculty of Medicine